$162 Million is the total value of VHCP Management III, LLC's 17 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GEMP | Exit | Gemphire Therapeutics | $0 | – | -798,066 | -100.0% | -0.30% | – |
| KDMN | Exit | Kadmon Holdings Inc. | $0 | – | -422,141 | -100.0% | -0.41% | – |
| ORTX | Exit | Orchard RX Ltd | $0 | – | -676,252 | -100.0% | -4.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kalvista Pharmaceuticals | 6 | Q4 2019 | 21.5% |
| Obseva SA | 6 | Q4 2019 | 15.8% |
| Constellation Pharmaceuticals | 6 | Q4 2019 | 23.5% |
| Marinus Pharmaceuticals Inc | 6 | Q4 2019 | 5.1% |
| Bellerophon Therapeutics | 6 | Q4 2019 | 1.9% |
| BioCryst Pharmaceuticals Inc | 5 | Q3 2019 | 18.0% |
| Tricida Inc | 5 | Q3 2019 | 15.0% |
| Protagonist Therapeutics Inc | 5 | Q4 2019 | 8.0% |
| Kiniksa Pharmaceuticals Ltd | 5 | Q3 2019 | 6.7% |
| Axsome Therapeutics Inc | 4 | Q4 2019 | 31.8% |
View VHCP Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-22 |
| 4 | 2024-02-08 |
| 4 | 2024-02-01 |
| 4 | 2024-01-29 |
| 4 | 2024-01-24 |
| 4 | 2024-01-19 |
| 4 | 2024-01-16 |
| 4 | 2024-01-10 |
| 4 | 2024-01-05 |
| 4 | 2023-12-29 |
View VHCP Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.